Rigel(DE:RI2)
€37.73-0.81 (-2.10%)
DE:RI2
Rigel stock drug pipeline
€37.73
At close:-0.81 (-2.10%)
Rigel (RI2) Drug Pipeline
1 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Rigel Pharmaceuticals (DE:RI2) have in its pipeline
Rigel DE:RI2 is currently developing the following drugs: Olutasidenib, Cyp1a2, Cyp2b6, Cyp2c8, Cyp2c9, Cyp2c19, Cyp3a4, And Oatp1b1 Probe Substrates, Olutasidenib + Tmz, Ly3871801, R906289 Monosodium, Fostamatinib, Fostamatinib Disodium, Fostamatinib 150 Mg Bid, Fostamatinib Disodium Tablet 100 Mg, Fostamatinib Disodium Tablet 150 Mg, Fostamatinib 150 Mg, Fostamatinib 100 Mg, R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, R932333, R940343 1Mg, R940343 2Mg, Fostamatinib Disodium / R935788. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

